Recent developments in the management of t-cell precursor acute lymphoblastic leukemia/lymphoma

Current Hematologic Malignancy Reports

Volumn 7, Issue 2, 2012, Pages 160-169

  Fielding, Adele K ^a   Banerjee, Lalita ^a   Marks, David I ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Adult; Chemotherapy; Genetics; Leukemia; Lymphoblastic; Lymphoma; Stem cell transplant; T precursor; Treatment

Indexed keywords

CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; FORODESINE; METHOTREXATE; NELARABINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GENETICS; HUMAN; LEUKEMOGENESIS; LYMPHOBLASTOMA; PHARMACOGENETICS; PRE T LYMPHOCYTE; REVIEW; RISK ASSESSMENT; T CELL LEUKEMIA; T CELL LYMPHOMA; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

ANTINEOPLASTIC AGENTS; DISEASE MANAGEMENT; ENZYME INHIBITORS; HUMANS; PHENOTYPE; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES;

EID: 84860841415     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-012-0123-4     Document Type: Review

References (82)

1. Dores GM, Devesa SS, Curtis RE, Linet MS, Morton LM. Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood. 2012;119 (1):34-43.
2. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107 (1):265-76. (Pubitemid 43053551)
3. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117 (19):5019-32.
4. Feng H, Stachura DL, White RM, et al. T-lymphoblastic lymphoma cells express high levels of BCL2, S1P1, and ICAM1, leading to a blockade of tumor cell intravasation. Cancer Cell. 2010;18 (4):353-66. An important paper examining the genetic basis for the difference between T-LBL and T-ALL. That AKT activation was identified as being important in controlling extravasation of T lymphoblasts suggests that PI3K-AKT inhibitors could be useful therapeutically, in preventing T-LBL cells from acquiring the ability to invade and disseminate.
5. Schatz DG, Oettinger MA, Schlissel MS. V(D)J recombination: molecular biology and regulation. Annu Rev Immunol. 1992;10:359-83.
6. Takahama Y. Journey through the thymus: stromal guides for T-cell development and selection. Nat Rev Immunol. 2006;6 (2):127-35. (Pubitemid 43361588)
7. Rothenberg EV, Taghon T. Molecular genetics of T cell development. Annu Rev Immunol. 2005;23:601-49. (Pubitemid 40563181)
8. Asnafi V, Beldjord K, Boulanger E, et al. Analysis of TCR, pT alpha, and RAG-1 in T-acute lymphoblastic leukemias improves understanding of early human T-lymphoid lineage commitment. Blood. 2003;101 (7):2693-703. (Pubitemid 36857632)
9. Bene MC. Pro-T ALL: immunophenotypical analyses. J Biol Regul Homeost Agents. 2004;18 (3-4):327-30.
10. Asnafi V, Beldjord K, Libura M, et al. Age-related phenotypic and oncogenic differences in T-cell acute lymphoblastic leukemias may reflect thymic atrophy. Blood. 2004;104 (13):4173-80. (Pubitemid 39620171)
11. Vitale A, Guarini A, Ariola C, et al. Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol. Blood. 2006;107 (2):473-9. (Pubitemid 43076367)
12. Meijerink JP. Genetic rearrangements in relation to immunophenotype and outcome in T-cell acute lymphoblastic leukaemia. Best Pract Res Clin Haematol. 2010;23 (3):307-18. A very clear and concise summary of the genetics of T ALL/LBL by an expert in the field.
13. Garand R, Voisin S, Papin S, et al. Characteristics of pro-T ALL subgroups: comparison with late T-ALL. The Groupe d'Etude Immunologique des Leucemies. Leukemia. 1993;7 (2):161-7. (Pubitemid 23079220)
14. Asnafi V, Buzyn A, Thomas X, et al. Impact of TCR status and genotype on outcome in adult T-cell acute lymphoblastic leukemia: a LALA-94 study. Blood. 2005;105 (8):3072-8.
15. Marks DI, Paietta EM, Moorman AV, et al. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). Blood. 2009;114 (25):5136-45. The largest and pivotal study of patients with T-ALL-includes information on genetics, prognostic factors, and outcomes after treatment with both chemotherapy and stem cell transplants.
16. Fischer L, Gokbuget N, Schwartz S, et al. CD56 expression in Tcell acute lymphoblastic leukemia is associated with non-thymic phenotype and resistance to induction therapy but no inferior survival after risk-adapted therapy. Haematologica. 2009;94 (2):224-9.
17. Coustan-Smith E, Mullighan CG, Onciu M, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 2009;10 (2):147-56. Describes the entity of ETP-ALL for the first time. Demonstrates the extremely poor prognosis, and makes clear that the early recognition of this entity is important in order to allow consideration of early therapeutic intensification.
18. Zhang J, Ding L, Holmfeldt L, et al. The genetic basis of early Tcell precursor acute lymphoblastic leukaemia. Nature. 2012;481 (7380):157-63. An insightful paper, examining the genetics of ETP-ALL by transcriptional profiling. Concludes that the transcriptional profile of ETP-ALL is similar to that of normal and myeloid leukemia hematopoietic stem cells suggesting that a change in therapeutic direction to therapy more commonly used for myeloid malignancies may benefit these patients.
19. Bergeron J, Clappier E, Radford I, et al. Prognostic and oncogenic relevance of TLX1/HOX11 expression level in T-ALLs. Blood. 2007;110 (7):2324-30. (Pubitemid 47523151)
20. Ferrando AA, Neuberg DS, Dodge RK, et al. Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia. Lancet. 2004;363 (9408):535-6. (Pubitemid 38229456)
21. Baak U, Gokbuget N, Orawa H, et al. Thymic adult T-cell acute lymphoblastic leukemia stratified in standard- and high-risk group by aberrant HOX11L2 expression: experience of the German multicenter ALL study group. Leukemia. 2008;22 (6):1154-60. (Pubitemid 351833782)
22. Krieger D, Moericke A, Oschlies I, et al. Frequency and clinical relevance of DNA microsatellite alterations of the CDKN2A/B, ATM and p53 gene loci: a comparison between pediatric precursor T-cell lymphoblastic lymphoma and T-cell lymphoblastic leukemia. Haematologica. 2010;95 (1):158-62.
23. Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004;306 (5694):269-71. (Pubitemid 39336870)
24. O'Neil J, Grim J, Strack P, et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gammasecretase inhibitors. J Exp Med. 2007;204 (8):1813-24. (Pubitemid 47236319)
25. Buonamici S, Trimarchi T, Ruocco MG, et al. CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia. Nature. 2009;459 (7249):1000-4.
26. Asnafi V, Buzyn A, Le Noir S, et al. NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study. Blood. 2009;113 (17):3918-24. Identifies a large group of patients with NOTCH1 or FBXW7 mutations who have a good outcome. Goes some way to explaining that could be why adult patients with TALL have relatively good outcomes.
27. Baldus CD, Thibaut J, Goekbuget N, et al. Prognostic implications of NOTCH1 and FBXW7 mutations in adult acute T-lymphoblastic leukemia. Haematologica. 2009;94 (10):1383-90.
28. Mansour MR, Sulis ML, Duke V, et al. Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol. J Clin Oncol. 2009;27 (26):4352-6.
29. Reiter A, Schrappe M, Ludwig WD, et al. Intensive ALL-type therapy without local radiotherapy provides a 90 % event-free survival for children with T-cell lymphoblastic lymphoma:A BFM group report. Blood. 2000;95 (2):416-21. (Pubitemid 30041651)
30. Thomas DA, O'Brien S, Cortes J, et al. Outcome with the hyper- CVAD regimens in lymphoblastic lymphoma. Blood. 2004;104 (6):1624-30. (Pubitemid 39202267)
31. Cairo MS, Coiffier B, Reiter A, Younes A. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol. 2010;149 (4):578-86.
32. Will A, Tholouli E. The clinical management of tumour lysis syndrome in haematological malignancies. Br J Haematol. 2011;154 (1):3-13.
33. Pui CH. Rasburicase: a potent uricolytic agent. Expert Opin Pharmacother. 2002;3 (4):433-42.
34. Annino L, Vegna ML, Camera A, et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood. 2002;99 (3):863-71. (Pubitemid 34525547)
35. Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005;106 (12):3760-7. (Pubitemid 41739010)
36. Larson RA, Dodge RK, Linker CA, et al. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood. 1998;92 (5):1556-64. (Pubitemid 28406859)
37. Kantarjian H, Thomas D, O'Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004;101 (12):2788-801. (Pubitemid 39603187)
38. Gokbuget N, Hoelzer D, Arnold R, et al. Treatment of adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin North Am. 000;14 (6):1307-25. ix.
39. Fiere D, Lepage E, Sebban C, et al. Adult acute lymphoblastic leukemia: a multicentric randomized trial testing bone marrow transplantation as postremission therapy. The French group on therapy for adult acute lymphoblastic leukemia. J Clin Oncol. 1993;11 (10):1990-2001. (Pubitemid 23304626)
40. Patel B, Rai L, Buck G, et al. Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993. Br J Haematol. 2010;148 (1):80-9.
41. Mortuza FY, Papaioannou M, Moreira IM, et al. Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. J Clin Oncol. 2002;20 (4):1094-104. (Pubitemid 34141855)
42. Bruggemann M, Raff T, Flohr T, et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood. 2006;107 (3):1116-23. (Pubitemid 43156313)
43. Bruggemann M, Schrauder A, Raff T, et al. Standardized MRD quantification in European ALL trials: proceedings of the second international symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia. 2010;24 (3):521-35.
44. Robillard N, Cave H, Mechinaud F, et al. Four-color flow cytometry bypasses limitations of IG/TCR polymerase chain reaction for minimal residual disease detection in certain subsets of hildren with acute lymphoblastic leukemia. Haematologica. 2005;90 (11):1516-23. (Pubitemid 41658765)
45. Coustan-Smith E, Song G, Clark C, et al. New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood. 2011;117 (23):6267-76.
46. Krampera M, Vitale A, Vincenzi C, et al. Outcome prediction by immunophenotypic minimal residual disease detection in adult T-cell acute lymphoblastic leukaemia. Br J Haematol. 2003;120 (1):74-9. (Pubitemid 36056911)
47. Bruggemann M, van der Velden VH, Raff T, et al. Rearranged Tcell receptor beta genes represent powerful targets for quantification of minimal residual disease in childhood and adult T-cell acute lymphoblastic leukemia. Leukemia. 2004;18 (4):709-19. (Pubitemid 38528651)
48. Sullivan MP, Boyett J, Pullen J, et al. Pediatric oncology group experience with modified LSA2-L2 therapy in 107 children with non-Hodgkin's lymphoma (Burkitt's lymphoma excluded). Cancer. 1985;55 (2):323-36. (Pubitemid 15152799)
49. Attarbaschi A, Mann G, Dworzak M, Wiesbauer P, Schrappe M, Gadner H. Mediastinal mass in childhood T-cell acute lymphoblastic leukemia: significance and therapy response. Med Pediatr Oncol. 2002;39 (6):558-65. (Pubitemid 35191438)
50. Hoelzer D, Gokbuget N, Digel W, et al. Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia. Blood. 2002;99 (12):4379-85. (Pubitemid 34627204)
51. Cheson BD. Role of functional imaging in the management of lymphoma. J Clin Oncol. 2011;29 (14):1844-54.
52. Feeney J, Horwitz S, Gonen M, Schoder H. Characterization of Tcell lymphomas by FDG PET/CT. AJR Am J Roentgenol. 2010;195 (2):333-40.
53. Meignan M, Gallamini A, Haioun C, Polliack A. Report on the second international workshop on interim positron emission tomography in lymphoma held in Menton, France, 8-9 April 2010. Leuk Lymphoma. 2010;51 (12):2171-80. A useful pragmatic summary of expert opinion on the role of PET in managing patients with lymphoma. Important topic for clinicians trying to decide how best to use PET in managing patients with T-LBL.
54. Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009;360 (26):2730-41.
55. Matloub Y, Lindemulder S, Gaynon PS, et al. Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the children's oncology group. Blood. 2006;108 (4):1165-73. (Pubitemid 44232011)
56. Clarke M, Gaynon P, Hann I, et al. CNS-directed therapy for childhood acute lymphoblastic leukemia: childhood ALL collaborative group overview of 43 randomized trials. J Clin Oncol. 2003;21 (9):1798-809. (Pubitemid 46646217)
57. Kager L, Cheok M, Yang W, et al. Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. J Clin Invest. 2005;115 (1):110-7. (Pubitemid 40385511)
58. Schrappe M, Reiter A, Zimmermann M, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALLBFM study group from 1981 to 1995. Berlin-Frankfurt-Munster. Leukemia. 2000;14 (12):2205-22. (Pubitemid 32042262)
59. Cortelazzo S, Intermesoli T, Oldani E, et al. Results of a lymphoblastic leukemia-like chemotherapy program with risk-adapted mediastinal irradiation and stem cell transplantation for adult patients with lymphoblastic lymphoma. Ann Hematol. 2012;91 (1):73-82.
60. Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood. 2008;111 (4):1827-33. (Pubitemid 351451489)
61. Milpied N, Ifrah N, Kuentz M, et al. Bone marrow transplantation for adult poor prognosis lymphoblastic lymphoma in first complete remission. Br J Haematol. 1989;73 (1):82-7. (Pubitemid 19237740)
62. Santini G, Coser P, Chisesi T, et al. Autologous bone marrow transplantation for advanced stage adult lymphoblastic lymphoma in first complete remission. Report of the Non-Hodgkin's Lymphoma Cooperative Study Group (NHLCSG). Ann Oncol. 1991;2 Suppl 2:181-5.
63. Verdonck LF, Dekker AW, de Gast GC, Lokhorst HM, Nieuwenhuis HK. Autologous bone marrow transplantation for adult poor-risk lymphoblastic lymphoma in first remission. J Clin Oncol. 1992;10 (4):644-6.
64. Sweetenham JW, Liberti G, Pearce R, Taghipour G, Santini G, Goldstone AH. High-dose therapy and autologous bone marrow transplantation for adult patients with lymphoblastic lymphoma: results of the European group for bone marrow transplantation. J Clin Oncol. 1994;12 (7):1358-65. (Pubitemid 24206232)
65. Sweetenham JW, Santini G, Qian W, et al. High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European group for blood and marrow transplantation and the United Kingdom lymphoma group. J Clin Oncol. 2001;19 (11):2927-36. (Pubitemid 32538203)
66. Hunault M, Truchan-Graczyk M, Caillot D, et al. Outcome of adult T-lymphoblastic lymphoma after acute lymphoblastic leukemiatype treatment: a GOELAMS trial. Haematologica. 2007;92 (12):1623-30. (Pubitemid 350248241)
67. Rodriguez Jr CO, Gandhi V. Arabinosylguanine-induced apoptosis of T-lymphoblastic cells: incorporation into DNA is a necessary step. Cancer Res. 1999;59 (19):4937-43. (Pubitemid 29472899)
68. Kurtzberg J, Ernst TJ, Keating MJ, et al. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol. 2005;23 (15):3396-403.
69. DeAngelo DJ, Yu D, Johnson JL, et al. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: cancer and leukemia group B study 19801. Blood. 2007;109 (12):5136-42. (Pubitemid 46890527)
70. Czuczman MS, Porcu P, Johnson J, et al. Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901. Leuk Lymphoma. 2007;48 (1):97-103. (Pubitemid 46978628)
71. Gokbuget N, Basara N, Baurmann H, et al. High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation. Blood. 2011;118 (13):3504-11. Largest study of patients with relapsed T-ALL/LBL. Demonstrates an important role for nelarabine in this patient population. Indicates why nelarabine is being studied "up front" in patients with newly diagnosed T-ALL by two major national ALL study groups.
72. Parker WB, Shaddix SC, Chang CH, et al. Effects of 2-chloro-9- (2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5?-triphosphate. Cancer Res. 1991;51 (9):2386-94.
73. Karp JE, Ricklis RM, Balakrishnan K, et al. A phase 1 clinicallaboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood. 007;110 (6):1762-9.
74. Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood. 2003;102 (7):2379-86. (Pubitemid 37193573)
75. Kicska GA, Long L, Horig H, et al. Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes. Proc Natl Acad SciU S A. 2001;98 (8):4593-8. (Pubitemid 32295021)
76. Homminga I, Zwaan CM, Manz CY, et al. In vitro efficacy of forodesine and nelarabine (ara-G) in pediatric leukemia. Blood. 2011;118 (8):2184-90.
77. Gandhi V, Kilpatrick JM, Plunkett W, et al. A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX- 1777, forodesine). Blood. 2005;106 (13):4253-60. (Pubitemid 41775934)
78. Palomero T, Dominguez M, Ferrando AA. The role of the PTEN/ AKT Pathway in NOTCH1-induced leukemia. Cell Cycle. 2008;7 (8):965-70. (Pubitemid 351679827)
79. Palomero T, Sulis ML, Cortina M, et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med. 2007;13 (10):1203-10. (Pubitemid 47530629)
80. Okuhashi Y, Itoh M, Nara N, Tohda S. Effects of combination of notch inhibitor plus hedgehog inhibitor or Wnt inhibitor on growth of leukemia cells. Anticancer Res. 2011;31 (3):893-6.
81. Rao SS, O'Neil J, Liberator CD, et al. Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells. Cancer Res. 2009;69 (7):3060-8.
82. Real PJ, Tosello V, Palomero T, et al. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med. 2009;15 (1):50-8.